These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 22437759)

  • 1. Role of transglutaminase 2 in celiac disease pathogenesis.
    Klöck C; Diraimondo TR; Khosla C
    Semin Immunopathol; 2012 Jul; 34(4):513-22. PubMed ID: 22437759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transglutaminase as a therapeutic target for celiac disease.
    Sulic AM; Kurppa K; Rauhavirta T; Kaukinen K; Lindfors K
    Expert Opin Ther Targets; 2015 Mar; 19(3):335-48. PubMed ID: 25410283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation and inhibition of transglutaminase 2 in mice.
    Dafik L; Albertelli M; Stamnaes J; Sollid LM; Khosla C
    PLoS One; 2012; 7(2):e30642. PubMed ID: 22319575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study.
    Rauhavirta T; Oittinen M; Kivistö R; Männistö PT; Garcia-Horsman JA; Wang Z; Griffin M; Mäki M; Kaukinen K; Lindfors K
    J Clin Immunol; 2013 Jan; 33(1):134-42. PubMed ID: 22878839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transglutaminase 2 inhibitors and their therapeutic role in disease states.
    Siegel M; Khosla C
    Pharmacol Ther; 2007 Aug; 115(2):232-45. PubMed ID: 17582505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic strategies for coeliac disease: tissue transglutaminase as a target.
    Esposito C; Caputo I; Troncone R
    Curr Med Chem; 2007; 14(24):2572-80. PubMed ID: 17979710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process.
    Fleckenstein B; Molberg Ø; Qiao SW; Schmid DG; von der Mülbe F; Elgstøen K; Jung G; Sollid LM
    J Biol Chem; 2002 Sep; 277(37):34109-16. PubMed ID: 12093810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
    Büchold C; Hils M; Gerlach U; Weber J; Pelzer C; Heil A; Aeschlimann D; Pasternack R
    Cells; 2022 May; 11(10):. PubMed ID: 35626704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutive Differential Features of Type 2 Transglutaminase in Cells Derived from Celiac Patients and from Healthy Subjects.
    Paolella G; Nanayakkara M; Sposito S; Lepretti M; Auricchio S; Esposito C; Barone MV; Martucciello S; Caputo I
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and evaluation of gluten peptide analogs as selective inhibitors of human tissue transglutaminase.
    Hausch F; Halttunen T; Mäki M; Khosla C
    Chem Biol; 2003 Mar; 10(3):225-31. PubMed ID: 12670536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transglutaminase 2-targeted autoantibodies in celiac disease: Pathogenetic players in addition to diagnostic tools?
    Lindfors K; Mäki M; Kaukinen K
    Autoimmun Rev; 2010 Sep; 9(11):744-9. PubMed ID: 20547248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transglutaminase 2 undergoes a large conformational change upon activation.
    Pinkas DM; Strop P; Brunger AT; Khosla C
    PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue transglutaminase-mediated formation and cleavage of histamine-gliadin complexes: biological effects and implications for celiac disease.
    Qiao SW; Piper J; Haraldsen G; Oynebråten I; Fleckenstein B; Molberg O; Khosla C; Sollid LM
    J Immunol; 2005 Feb; 174(3):1657-63. PubMed ID: 15661929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced B-Cell Receptor Recognition of the Autoantigen Transglutaminase 2 by Efficient Catalytic Self-Multimerization.
    Stamnaes J; Iversen R; du Pré MF; Chen X; Sollid LM
    PLoS One; 2015; 10(8):e0134922. PubMed ID: 26244572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
    Song M; Hwang H; Im CY; Kim SY
    J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-γ activates transglutaminase 2 via a phosphatidylinositol-3-kinase-dependent pathway: implications for celiac sprue therapy.
    Diraimondo TR; Klöck C; Khosla C
    J Pharmacol Exp Ther; 2012 Apr; 341(1):104-14. PubMed ID: 22228808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are Peptide fragments harboring celiac disease T-cell epitopes.
    Dørum S; Arntzen MØ; Qiao SW; Holm A; Koehler CJ; Thiede B; Sollid LM; Fleckenstein B
    PLoS One; 2010 Nov; 5(11):e14056. PubMed ID: 21124911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transglutaminase 2 in celiac disease: minireview article.
    Caputo I; D'Amato A; Troncone R; Auricchio S; Esposito C
    Amino Acids; 2004 Jul; 26(4):381-6. PubMed ID: 15290344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of cell surface TG2 in the aggregation of K562 cells triggered by gluten.
    Feriotto G; Calza R; Bergamini CM; Griffin M; Wang Z; Beninati S; Ferretti V; Marzola E; Guerrini R; Pagnoni A; Cavazzini A; Casciano F; Mischiati C
    Amino Acids; 2017 Mar; 49(3):551-565. PubMed ID: 27699491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards Celiac-safe foods: Decreasing the affinity of transglutaminase 2 for gliadin by addition of ascorbyl palmitate and ZnCl
    Engstrom N; Saenz-Méndez P; Scheers J; Scheers N
    Sci Rep; 2017 Mar; 7(1):77. PubMed ID: 28250436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.